Alexion Pharmaceuticals Inc. (ALXN) Release: New Data Presented At The ERA-EDTA Congress Demonstrate Efficacy Of Soliris® (Eculizumab) In Broad Range Of Patients With Atypical Hemolytic Uremic Syndrome (Ahus)
6/2/2014 9:00:16 AM
CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that researchers presented data from clinical trials supporting the chronic use of Soliris® (eculizumab) in a broad range of patients with atypical hemolytic uremic syndrome (aHUS), a genetic, chronic, ultra-rare disease associated with vital organ failure and premature death.
Help employers find you! Check out all the jobs and post your resume.
comments powered by